P. Caron et al., 3-YEAR FOLLOW-UP OF ACROMEGALIC PATIENTS TREATED WITH INTRAMUSCULAR SLOW-RELEASE LANREOTIDE, The Journal of clinical endocrinology and metabolism, 82(1), 1997, pp. 18-22
Somatostatin analogs are an alternative treatment to pituitary surgery
and radiotherapy in acromegalic patients. Recently, a depot long-last
ing formulation of slow release (SR) lanrectide has been shown to be e
ffective in the short-term control of GH hypersecretion in acromegalic
patients. We report the long-term follow-up of a cohort of 22 acromeg
alic patients treated with SR lanreotide during 1-3 yr. Thirteen femal
es and 9 males, age 51 +/- 3 yr, presented with macroadenomas (n = 12)
, microadenomas (n = 8), or empty sella (n = 2). Seven patients previo
usly had undergone a partial surgical removal of their adenomas, and 2
1 of them has mean plasma GH levels less than 5 mu g/L during a previo
us octreotide treatment. According to GH values recorded after 3 month
s of twice monthly 30 mg SR lanreotide im injection, SR lanreotide was
administered every 14 days (n = 13) or every 10 days (n = 9). At the
6-month visit, mean GH values were 5 mu g/L or less in 68% and 2.5 mu
g/L or less in 27% of patients, and these results remained unchanged d
uring the 1-3 yr follow-up period. During SR lanreotide treatment, the
mean insulin-like growth factor I (IGF-I) concentrations remained in
the normal range in 63% of patients. No escape from the treatment occu
red in any of the cases. A significant decrease of the pituitary tumor
volume was observed in 3 (13%) patients. The main side effect consist
ed of minor digestive problems during 48 h after each injection and wa
s reported by 13 patients. Biannual gallbladder echographies revealed
the occurence of gallstones in 4 (18%) patients. In conclusion, these
data confirms the efficacy and the tolerance of the long-term SR lanre
otide administration (30 mg im every 10-14 days) in the control of acr
omegaly.